ALKS
Price
$31.78
Change
+$1.20 (+3.92%)
Updated
May 2 closing price
Capitalization
4.55B
80 days until earnings call
AMPH
Price
$24.50
Change
+$0.62 (+2.60%)
Updated
May 2 closing price
Capitalization
2.11B
3 days until earnings call
Ad is loading...

ALKS vs AMPH

Header iconALKS vs AMPH Comparison
Open Charts ALKS vs AMPHBanner chart's image
Alkermes
Price$31.78
Change+$1.20 (+3.92%)
Volume$3.46M
Capitalization4.55B
Amphastar Pharmaceuticals
Price$24.50
Change+$0.62 (+2.60%)
Volume$674.1K
Capitalization2.11B
ALKS vs AMPH Comparison Chart
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AMPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. AMPH commentary
May 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Buy and AMPH is a Buy.

Ad is loading...
COMPARISON
Comparison
May 04, 2025
Stock price -- (ALKS: $31.78 vs. AMPH: $24.50)
Brand notoriety: ALKS and AMPH are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 186% vs. AMPH: 103%
Market capitalization -- ALKS: $4.55B vs. AMPH: $2.11B
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. AMPH’s [@Pharmaceuticals: Other] market capitalization is $2.11B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 2 FA rating(s) are green whileAMPH’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 2 green, 3 red.
  • AMPH’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than AMPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while AMPH’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 6 bearish.
  • AMPH’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, AMPH is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а +14.15% price change this week, while AMPH (@Pharmaceuticals: Other) price change was +1.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.04%. For the same industry, the average monthly price growth was +3.46%, and the average quarterly price growth was -7.03%.

Reported Earning Dates

ALKS is expected to report earnings on Jul 23, 2025.

AMPH is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.04% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than AMPH($2.11B). AMPH has higher P/E ratio than ALKS: AMPH (16.69) vs ALKS (8.90). ALKS YTD gains are higher at: 10.501 vs. AMPH (-34.016). ALKS has higher annual earnings (EBITDA): 519M vs. AMPH (240M). ALKS has more cash in the bank: 773M vs. AMPH (257M). ALKS has less debt than AMPH: ALKS (372M) vs AMPH (624M). ALKS has higher revenues than AMPH: ALKS (1.66B) vs AMPH (644M).
ALKSAMPHALKS / AMPH
Capitalization4.55B2.11B215%
EBITDA519M240M216%
Gain YTD10.501-34.016-31%
P/E Ratio8.9016.6953%
Revenue1.66B644M258%
Total Cash773M257M301%
Total Debt372M624M60%
FUNDAMENTALS RATINGS
ALKS vs AMPH: Fundamental Ratings
ALKS
AMPH
OUTLOOK RATING
1..100
305
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
1977
SMR RATING
1..100
3540
PRICE GROWTH RATING
1..100
4992
P/E GROWTH RATING
1..100
1195
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMPH's Valuation (62) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALKS (99) in the Biotechnology industry. This means that AMPH’s stock grew somewhat faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (19) in the Biotechnology industry is somewhat better than the same rating for AMPH (77) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew somewhat faster than AMPH’s over the last 12 months.

ALKS's SMR Rating (35) in the Biotechnology industry is in the same range as AMPH (40) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew similarly to AMPH’s over the last 12 months.

ALKS's Price Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for AMPH (92) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew somewhat faster than AMPH’s over the last 12 months.

ALKS's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for AMPH (95) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew significantly faster than AMPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSAMPH
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
57%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
64%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 5 days ago
72%
Declines
ODDS (%)
Bearish Trend 17 days ago
62%
Bearish Trend 3 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
61%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
72%
View a ticker or compare two or three
Ad is loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AMPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TNA27.641.72
+6.64%
Direxion Daily Small Cap Bull 3X ETF
PYZ84.111.27
+1.53%
Invesco DW Basic Materials Momt ETF
PGHY19.520.02
+0.10%
Invesco Glb ex-US High Yld Corp Bd ETF
XDOC29.04N/A
N/A
Innovator US Equity Accelerated ETF Oct
MUA10.29-0.01
-0.10%
Blackrock Muni Assets Fund

ALKS and

Correlation & Price change

A.I.dvisor tells us that ALKS and ESPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALKS and ESPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+3.92%
ESPR - ALKS
32%
Poorly correlated
+10.77%
VTRS - ALKS
32%
Poorly correlated
+2.13%
DVAX - ALKS
32%
Poorly correlated
-1.31%
ACET - ALKS
30%
Poorly correlated
+6.60%
EOLS - ALKS
30%
Poorly correlated
+2.37%
More

AMPH and

Correlation & Price change

A.I.dvisor tells us that AMPH and COLL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMPH and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMPH
1D Price
Change %
AMPH100%
+2.60%
COLL - AMPH
31%
Poorly correlated
+2.18%
AMRX - AMPH
31%
Poorly correlated
+2.97%
ALKS - AMPH
30%
Poorly correlated
+3.92%
EOLS - AMPH
29%
Poorly correlated
+2.37%
DVAX - AMPH
28%
Poorly correlated
-1.31%
More